Hepatocellular carcinoma
Conditions
Interventions
Gold Standard:Dynamic contrast-enhanced CT or MRI: The typical manifestation is that the lesion is significantly enhanced in the arterial phase, while the enhancement decreases in the portal vein phas
Index test:A risk prediction model for non-local UER based on these independent risk factors
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with primary treatment or recurrent disease after radical therapy and refuse surgical resection; 2. Single tumor with a maximum diameter of <=5.0 cm; 3. Multiple tumors, number <=3, with a maximum diameter of <=3.0 cm; 4. No major vascular invasion, no lymph node or extrahepatic metastasis; 5. Performance status with an Eastern Cooperative Oncology Group score of 0; 6. Child-Pugh Class A; 7. No other malignant tumors; 8. Pre-procedure magnetic resonance imaging (MRI) scan completed within one month; 9. Dynamic enhanced CT or MRI scan confirming complete ablation one month after procedure; 10. Post-procedure follow-up until the first recurrence or for no less than one year.
Exclusion criteria
Exclusion criteria: 1. Lack of complete imaging data, including T2-weighted imaging (T2WI) and dynamic contrast-enhanced imaging. (2) Significant motion artifacts on MRI. (3) Concurrent transcatheter arterial chemoembolization (TACE) (excluding the risk validation set).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Specificity;non-local ultra early recurrence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity;AUC of ROC;Lesion detection rate;recurrence-free survival;accuracy;Overall survival;negative predictive value;positive predictive value; | — |
Countries
China
Contacts
Public ContactHu Hongtao
Henan Cancer Hospital
Outcome results
None listed